Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: Arwa Farag, Athena Papas, Benjamin Fisher, Margit Zeher, Wan-Fai Ng, Michele Bombardieri, Maximilian Posch, Thomas Daikeler, Bettina Bannert, Alan Kivitz, Steven Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espie, Grazyna Wieczorek, Pierre Moulin, David Floch, Cyrielle Dupuy, Xiaohui Ren, Petra Faerber, Andrew Wright, Hans Ulrich Hockey, Michael Rotte, James Rush, Peter Gergely
Institutions: Tufts University, King Abdulaziz University, University of Birmingham, University of Debrecen, Newcastle upon Tyne Hospitals NHS Foundation Trust, Queen Mary University of London, William Harvey Research Institute, Charité – Universitätsmedizin Berlin, University Hospital of Basel, Altoona Center for Clinical Research, Winthrop-University Hospital, Stony Brook University, University College Hospital, University Hospitals Birmingham NHS Foundation Trust
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2895966166